Altimmune, Inc. (ALT)
$
3.62
+0.06 (1.66%)
Key metrics
Financial statements
Free cash flow per share
-1.0013
Market cap
319.5 Million
Price to sales ratio
16 Thousand
Debt to equity
0.0982
Current ratio
20.4362
Income quality
0.9296
Average inventory
0
ROE
-0.6263
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for obesity and liver diseases. Its lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), acts as a GLP-1/glucagon dual receptor agonist and is currently undergoing a Phase 1b clinical trial targeting obesity and non-alcoholic steatohepatitis. Additionally, Altimmune is advancing HepTcell, an immunotherapeutic product candidate in Phase 2 trials for patients with chronic hepatitis B virus infections. The company incurred an interest expense of $9,000.00 reflecting its debt servicing obligations. The financial data pertains to the fiscal year 2024. Furthermore, the diluted EPS is -$1.34 accounting for potential share dilution, while the net income ratio stands at -4,752.95 showcasing the company's profitability margin. The operating income ratio is -5,158.60 indicating the company's operational profitability margin. Founded in 1997 and rebranded from Vaxin Inc. in September 2015, Altimmune is headquartered in Gaithersburg, Maryland. In the financial landscape, Altimmune's stock is currently affordable at $4.26 making it suitable for budget-conscious investors. The stock has a high average trading volume of 5,832,243.00 indicating robust liquidity that attracts traders. With a market capitalization of $319,491,426.00 the company is classified as a small-cap player, which often allows for significant growth potential. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Moreover, it belongs to the Healthcare sector, where it is driving innovation and growth, highlighting its role in shaping future therapies and treatments in its field.
Is Altimmune, Inc. (ALT) a good investment?
Investing in Altimmune, Inc. (ALT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Altimmune, Inc. (ALT)'s stock forecast?
Analysts predict Altimmune, Inc. stock to fluctuate between $2.90 (low) and $11.16 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Altimmune, Inc.'s market capitalization?
As of 2025-08-20, Altimmune, Inc.'s market cap is $319,491,426, based on 88,257,300 outstanding shares.
How does Altimmune, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Altimmune, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Altimmune, Inc. pay dividends?
Altimmune, Inc. pays dividends. The current dividend yield is 1,310.82%, with a payout of $291 per share.
How can I buy Altimmune, Inc. (ALT) stock?
To buy Altimmune, Inc. (ALT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALT. Place an order (Market, Limit, etc.).
What is the best time to invest in Altimmune, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Altimmune, Inc. stock ever split?
Altimmune, Inc.'s last stock split was 1:30 on 2018-09-14.
How did Altimmune, Inc. perform in the last earnings report?
Revenue: $20,000 | EPS: -$1.34 | Growth: -19.28%.
Where can I find Altimmune, Inc.'s investor relations reports?
Visit https://altimmune.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Altimmune, Inc.?
You can explore historical data from here
What is the all-time high and low for Altimmune, Inc. stock?
All-time high: $23.49 (2022-09-02) | All-time low: $2.09 (2023-10-23).
What are the key trends affecting Altimmune, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NEW YORK, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit.
prnewswire.com
NEW YORK , Aug. 19, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Altimmune investors who were adversely affected by alleged securities fraud between August 10, 2023 and June 25, 2025.
globenewswire.com
Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder (AUD).
prnewswire.com
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than October 6, 2025.
prnewswire.com
NEW YORK , Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT). Shareholders who purchased shares of ALT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
globenewswire.com
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
prnewswire.com
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
globenewswire.com
NEW YORK, Aug. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025 (the “Class Period”), of the important October 6, 2025 lead plaintiff deadline.
prnewswire.com
PHILADELPHIA , Aug. 15, 2025 /PRNewswire/ -- Berger Montague PC is investigating potential securities fraud claims on behalf of investors of Altimmune, Inc. (NASDAQ: ALT) ("Altimmune" or the "Company") following the filing of a securities class action lawsuit filed on behalf of investors who purchased or otherwise acquired Altimmune securities between August 10, 2023 through June 25, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired Altimmune securities during the Class Period may, no later than October 6, 2025 , seek to be appointed as a lead plaintiff representative of the class.
prnewswire.com
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK , Aug. 15, 2025 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) and reminds investors of the October 6, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
See all news
